Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000766627 | SCV000242344 | uncertain significance | not provided | 2024-08-09 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Athena Diagnostics | RCV000188720 | SCV000614762 | uncertain significance | not specified | 2016-11-14 | criteria provided, single submitter | clinical testing | |
Genomic Research Center, |
RCV000661982 | SCV000784313 | uncertain significance | Neuronal ceroid lipofuscinosis 1 | 2018-03-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000661982 | SCV001005829 | benign | Neuronal ceroid lipofuscinosis 1 | 2024-01-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002345676 | SCV002645092 | uncertain significance | Inborn genetic diseases | 2020-03-18 | criteria provided, single submitter | clinical testing | The p.R179C variant (also known as c.535C>T), located in coding exon 5 of the PPT1 gene, results from a C to T substitution at nucleotide position 535. The arginine at codon 179 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000661982 | SCV001460032 | benign | Neuronal ceroid lipofuscinosis 1 | 2020-04-30 | no assertion criteria provided | clinical testing |